Top

Published in:

Open Access 01-04-2012 | Breast Oncology

Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer

Authors: C. J. Wink, MD, K. Woensdregt, MD, G. A. P. Nieuwenhuijzen, MD, PhD, M. J. C. van der Sangen, MD, S. Hutschemaekers, MD, J. A. Roukema, MD, PhD, V. C. G. Tjan-Heijnen, MD, PhD, A. C. Voogd, PhD

Published in: Annals of Surgical Oncology | Issue 4/2012

Abstract

Purpose

To evaluate the trend in the use of primary endocrine treatment (PET) for elderly patients with operable breast cancer and to study mean time to response (TTR), local control, time to progression (TTP), and overall survival.

Methods

Data of 184 patients aged ≥75 years, diagnosed with breast cancer in the south of the Netherlands between 2001 and 2008 and receiving PET, were analyzed.

Results

The percentage of women ≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988–1992 to 12% in 1997–2000, and increased to 29% in 2005–2008. Mean age at diagnosis of 184 patients treated with PET in the period 2001–2008 was 84 years (range 75–89 years). Mean length of follow-up was 2.6 years. In 107 patients (58%), an initial response was achieved (mean TTR 7 months), 21 patients (12%) showed stable disease. A total of 64 patients (35%), with or without prior response, eventually displayed progression (mean TTP 20 months). No differences in TTR and TTP were observed between the patients starting with tamoxifen or an aromatase inhibitor. One hundred nineteen (65%) of 184 patients had died by January 1, 2010. In 17 patients (14%), breast cancer was the cause of death.

Conclusions

Tumor progression was observed in a substantial proportion of the cohort, but only a small number of patients died of breast cancer. Further research is needed on the safety and effectiveness of PET for elderly women with breast cancer to justify the current widespread use.

Bergman L, Kluck HM, van Leeuwen FE, et al. The influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: a population-based study. Eur J Cancer. 1992;28A(8–9):1475–80.PubMedCrossRef

Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Breast cancer treatment guidelines in older women. J Clin Oncol. 2005;23:783–91.PubMedCrossRef

Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21:3580–7.PubMedCrossRef

Lavelle K, Todd C, Moran A, Howell A, Bundred N, Campbell M. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or = 65 years. Br J Cancer. 2007;96:1197–203.PubMedCrossRef

Wyld L, Garg DK, Kumar ID, Brown H, Reed MW. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer. 2004;90:1486–91.PubMedCrossRef

Velanovich V, Gabel M, Walker EM, et al. Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients. J Am Coll Surg. 2002;194:8–13.PubMedCrossRef

Hooper SB, Hill AD, Kennedy S, et al. Tamoxifen as the primary treatment in elderly patients with breast cancer. Ir J Med Sci. 2002;171:28–30.PubMedCrossRef

Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92:550–6.PubMedCrossRef

McCarty KS Jr, Silva JS, Cox EB, Leight GS Jr, Wells SA Jr, McCarty KS Sr. Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast. Ann Surg. 1983;197:123–7.PubMedCrossRef

10.

Hind D, Wyld L, Reed MW. Surgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane review. Br J Cancer. 2007;96:1025–9.PubMedCrossRef

11.

Seo JH, Kim YH, Kim JS. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor–positive breast cancer. Cancer Chemother Pharmacol. 2009;63:261–6.PubMedCrossRef

12.

Mathew J, Asgeirsson KS, Jackson LR, Cheung KL, Robertson JF. Neoadjuvant endocrine treatment in primary breast cancer—review of literature. Breast. 2009;18:339–44.PubMedCrossRef

13.

Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.PubMedCrossRef

14.

Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–32.PubMedCrossRef

15.

Bates T, Riley DL, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg. 1991;78:591–4.

16.

Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blarney RW. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast. 1998;7:335–9.CrossRef

17.

Willsher PC, Robertson JFR, Jackson L, Al-Hilaly M, Blarney RW. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast. 1997;6:150–4.CrossRef

18.

Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 1988;297(6647):511–4.PubMedCrossRef

19.

Chakrabarti J, Kenny FS, Syed BM, Robertson JF, Blamey RW, Cheung KL. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer—final results at 20-year follow-up. Crit Rev Oncol Hematol. 2011;78:260–4.PubMedCrossRef

20.

Syed BM, Al-Khyatt W, Johnston SJ, et al. Long-term clinical outcome of oestrogen receptor positive operable primary breast cancer in older women: a large series from a single centre. Br J Cancer. 2011;104:1393–400.PubMedCrossRef

21.

Breast Cancer Clinical Outcome Measures Project. (BCCOM). Analysis of the management of symptomatic breast cancers diagnosed in 2004, 3rd year report. 2007. www.baso.org.uk/Downloads/BCCOM_AR09.pdf.

22.

Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005;41:779–85.PubMedCrossRef

23.

Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMed

24.

Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704.PubMedCrossRef

Title: Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer
Authors: C. J. Wink, MD
K. Woensdregt, MD
G. A. P. Nieuwenhuijzen, MD, PhD
M. J. C. van der Sangen, MD
S. Hutschemaekers, MD
J. A. Roukema, MD, PhD
V. C. G. Tjan-Heijnen, MD, PhD
A. C. Voogd, PhD
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-2070-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

The Combined Expression of Metaplasia Biomarkers Predicts the Prognosis Of Gastric Cancer

Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period

Risk Factors for Bronchopleural Fistula After Right Pneumonectomy: Does Eliminating the Stump Diverticulum Provide Protection?

A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases

Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132

High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma